Calretinin-immunoreactive dopaminergic neurons from embryonic rat mesencephalon are resistant to levodopa-induced neurotoxicity

Experimental Neurology

Volumn 146, Issue 1, 1997, Pages 25-32

  Isaacs, Krystyna R ^a   Wolpoe, Matthew E ^a   Jacobowitz, David M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETININ; LEVODOPA;

ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CYTOPATHOGENIC EFFECT; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; EMBRYO; MESENCEPHALON; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT;

EID: 0031194653     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6530     Document Type: Article

References (65)

1. 1. Andressen, C., I. Blümcke, and M. R. Celio. 1993. Calcium-binding proteins: Selective markers of nerve cells. Cell Tissue Res. 271: 181-208.
2. 2. Arai, R., L. Winsky, M. Arai, and D. M. Jacobowitz. 1991. Immunohistochemical localization of calretinin in the rat hindbrain. J. Comp. Neurol. 310: 21-14.
3. 3. Baimbridge, K. G., M. R. Celio, and J. H. Rogers. 1992. Calcium-binding proteins in the nervous system. Trends Neurosci. 15: 303-308.
4. 4. Belichenko, P. V., D. M. Vogt Weisenhorn, J. Myklossy, and M. R. Celio. 1995. Calretinin-positive Cajal-Retzius cells persist in the adult human neocortex. Neuroreport 6: 1869-74.
5. 5. Blunt, S. B., P. Jenner, and C. D. Marsden. 1993. Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Disord. 8: 129-133.
6. 6. Chard, P. S., J. Jordan, C. J. Marcuccilli, R. J. Miller, J. M. Leiden, R. P. Roos, and G. D. Ghadge. 1995. Regulation of excitatory transmission at hippocampal synapses by calbindin D28k. Proc. Natl. Acad. Sci. USA 92: 5144-5148.
7. 7. Cleeter, M. W., J. M. Cooper, and A. H. V. Schapira. 1992. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement. J. Neurochem. 58: 786-9.
8. 8. Cook, J. A., D. A. Wink, V. Blount, M. C. Krishna, and I. Hanbauer. 1996. Role of antioxidants in the nitric oxide-elicited inhibition of dopamine uptake in cultured mesencephalic neurons. Insights into potential mechanisms of nitric oxide-mediated neurotoxicity. Neurochem. Intl. 28: 609-617.
9. 9. Dowd, D. R., P. N. MacDonald, B. S. Komm, M. R. Haussler, and R. L. Miesfeld. 1992. Stable expression of the calbindin D28K complementary DNA interferes with the apoptotic pathway in lymphocytes. Mol. Endocrinol. 6: 1843-1848.
10. +: Implications for neurodegeneration. J. Neurochem. 63: 584-591.
11. 11. Fahn, S. 1996. Is levodopa toxic? Neurology 47: S184-S195.
12. 12. Fonseca, M., and E. Soriano. 1995. Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer's disease. Brain Res. 691: 83-91.
13. 13. Fukuda, T., K. Watabe, and J. Tanaka. 1996. Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res. 728: 274-276.
14. 14. Gaspar, P., N. B. Jelloun, and A. Febvret. 1994. Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice. Neuroscience 61: 293-305.
15. 15. German, D. C., K. F. Manaye, P. K. Sonsalla, and B. A. Brooks. 1992. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. N.Y. Acad. Sci. 648: 42-62.
16. 16. Haber, S. N., H. Ryoo, C. Cox, and W. Lu. 1995. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: Comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol. 362: 400-410.
17. 17. Hefti, F., E. Melamed, J. Bhawan, and R. Wurtman. 1981. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse. Neurology 31: 1194-1195.
18. 2+-binding proteins in human neurodegenerative disorders. Trends Neurosci. 5: 259-264.
19. 28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: Normal distribution and distribution in Parkinson's disease. Neurodegeneration 1: 83-93.
20. 20. Ho, B. K., M. E. Alexianu, L. V. Colom, A. H. Mohamed, F. Serrano, and S. H. Appel. 1996. Expression of calbindin-D28k in motoneuron hybrid cells after retroviral infection with calbindin D28k cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 93: 6796-6801.
21. 28K-containing neurons in animal models of neurodegeneration: Possible protection from excitotoxicity. Mol. Brain Res. 13: 251-261.
22. 28K: A potential neuroprotective protein. Neurodegeneration 3: 1-20.
23. 23. Isaacs, K. R., G. de Erausquin, K. I. Strauss, D. M. Jacobowitz, and I. Hanbauer. 1996. Differential effects of excitatory amino acids on mesencephalic neurons expressing either calretinin or tyrosine hydroxylase in primary cultures. Mol. Brain Res. 36: 114-126.
24. 24. Isaacs, K. R., and D. M. Jacobowitz. 1994. Mapping of the colocalization of calretinin and tyrosine hydroxylase in the rat substantia nigra and ventral tegmental area. Exp. Brain Res. 99: 34-42.
25. 25. Jacobowitz, D. M., and L. Winsky. 1991. Immunocytochemical localization of calretinin in the forebrain of the rat. J. Comp. Neurol. 304: 198-218.
26. 26. Jenner, P. 1995. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45: S6-S12.
27. 2+-overload or trophic factor deprivation. Biophys. Biochem. Acta 1313: 194-200.
28. 2+-dependent conformational changes of calretinin by limited tryptic proteolysis. Biochem. J. 308: 607-612.
29. 29. Kuźnicki, J., L. Winsky, and D. M. Jacobowitz. 1994. Calcium dependent and independent interactions of calretinin with hydrophobic resins. Biochem. Mol. Biol. Int. 33: 713-721.
30. 30. Lavoie, B., and A. Parent. 1991. Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. Neuroreport 2: 601-604.
31. 31. Lledo, P.-M., B. Somasundaram, A. J. Morton, P. C. Emson, and W. T. Mason. 1992. Stable transfection of calbindin-D28k into the GH3 cell line alters calcium currents and intracellular calcium homeostasis. Neuron 9: 943-954.
32. 32. Lukas, W., and K. A. Jones. 1994. Cortical neurons containing calretinin are selectively resistant to calcium overload and excitotoxicity in vitro. Neuroscience 61: 307-316.
33. 33. McRitchie, D. A., and G. M. Halliday. 1995. Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans. Neuroscience 65: 87-91.
34. 34. McRitchie, D. A., C. D. Hardman, and G. M. Halliday. 1996. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 364: 121-50.
35. 35. Mena, M. A., B. Pardo, C. L. Paino, and J. Garcia de Yebenes. 1993. Levodopa toxicity in foetal rat midbrain neurones in culture: Modulation by ascorbic acid. Neuroreport 4: 438-440.
36. 36. Michel, P. P., and F. Hefti. 1990. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26: 428-435.
37. 28K. Brain Res. 648: 109-120.
38. 38. Montpied, P., L. Winsky, J. W. Dailey, P. C. Jobe, and D. M. Jacobowitz. 1995. Alteration in the levels of expression of brain calbindin D28k and calretinin mRNA in genetically epilepsy-prone rats. Epilepsia 36: 911-921.
39. 39. Mouatt-Prigent, A., Y. Agid, and E. C. Hirsh. 1994. Does the calcium-binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res. 668: 62-70.
40. 40. Muir, E. M., D. E. Lawson, F. V. Sepulveda, J. A. O'Brien, and A. Harding. 1993. Calbindin D28k expression in transfected NIH3T3 cells. Cell Calcium 14: 349-358.
41. 41. Muthane, U., K. A. Ramsay, H. Jiang, V. Jackson-Lewis, D. Donaldson, S. Fernando, M. Ferreira, and S. Przedborski. 1994. Differences in nigral number and sensitivity to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp. Neurol. 126: 195-204.
42. 42. Mytilineou, C., S-K. Han, and G. Cohen. 1993. Toxic and protective effects of L-DOPA on mesencephalic cultures. J. Neurochem. 61: 1470-1478.
43. 43. Ng, M., A. M. Iacopino, E. M. Quintero, F. Marches, P. K. Sonsalla, C.-L. Liang, S. G. Speciale, and D. C. German. 1996. The neurotoxin MPTP increases calbindin D28k levels in mouse midbrain dopaminergic neurons. Mol. Brain Res. 36: 329-336.
44. 44. Pardo, B., M. A. Mena, and J. Garcia de Yebenes. 1995. L-DOPA inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J. Neurochem. 64: 576-582.
45. 45. Parent, A., F. Cicchetti, and T. G. Beach. 1995. Calretinin-immunoreactive neurons in the human striatum. Brain Res. 674: 347-51.
46. 46. Park, J. S., M. C. Bateman, and M. P. Goldberg. 1996. Rapid alterations in dendrite morphology during sublethal hypoxia or glutamate receptor activation. Neurobiol. Disease 3: 215-227.
47. 47. Perry, T. L., V. W. Yong, M. Ito, J. G. Foulks, R. A. Wall, D. V. Godin, and R. M. Clavier. 1984. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J. Neurochem. 43: 990-993.
48. 48. Przedborski, S., V. Jackon-Lewis, and S. Fahn. 1995. Antiparkinsonian therapies and brain mitochondrial complex I activity. Mov. Disord. 10: 312-317.
49. 49. Przedborski, S., V. Jackson-Lewis, U. Muthane, H. Jiang, M. Ferreira, A. B. Naini, and S. Fahn. 1993. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 34: 715-723.
50. 50. Résibois, A., and J. H. Rogers. 1992. Calretinin in rat brain: An immuno-histochemical study. Neuroscience 46: 101-134.
51. 51. Rogers, J. H. 1992. Immunohistochemical markers in rat brain: colocalization of calretinin and calbindin-D28K with tyrosine hydroxylase. Brain Res. 587: 203-210.
52. 52. Schapira, A. H. V. 1994. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov. Disord. 9: 125-138.
53. 53. Schapira, A. H. V., J. M. Cooper, D. Dexter, J. B. Clark, P. Jenner, and C. D. Marsden. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54: 823-827.
54. 54. Schramm, M., S. Eimerl, and E. Costa. 1990. Serum and depolarizing agents cause acute neurotoxicity in cultured cerebellar granule cells: Role of the glutamate receptor responsive to N-methyl-D-aspartate. Proc. Natl. Acad. Sci. USA 87: 1193-1197.
55. 55. Smith, T. S., W. D. Parker, and J. P. Bennett. 1994. L-DOPA increases nigral production of hydroxyl radicals in vivo: Potential L-DOPA toxicity? Neuroreport 5: 1009-1011.
56. 56. Steece-Collier, K., T. J. Collier, C. D. Sladek, and J. R. Sladek. 1990. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp. Neurol. 110: 201-208.
57. 57. Strauss, K. I., D. M. Jacobowitz, and J. Schulkin. 1994. Dietary calcium deficiency causes a reduction in calretinin mRNA in the substantia nigra compacta-ventral tegmental area of rat brain. Mol. Brain Res. 25: 140-142.
58. 58. Strauss, K. I., J. Schulkin, and D. M. Jacobowitz. 1995. Corticosterone effects on rat calretinin mRNA in discrete brain nuclei and the testes. Mol. Brain Res. 28: 81-86.
59. 59. Takeshima, T., K. Shimoda, J. M. Johnston, and J. W. Commissiong. 1996. Standardized methods to bioassay neurotrophic factors for dopaminergic neurons. J. Neurosci. Methods 67: 27-41.
60. 60. Takeyama, N., N. Matsuo, and T. Tanaka. 1993. Oxidative damage to mitochondria is mediated by the Ca2+-dependent inner-membrane permeability transition. Biochem. J. 294: 719-725.
61. 61. Winsky, L., and D. M. Jacobowitz. 1995. Effects of unilateral cochlea ablation on the distribution of calretinin mRNA and immunoreactivity in the guinea pig ventral cochlear nucleus. J. Comp. Neurol. 354: 564-582.
62. 62. Winsky, L., and J. Kuźnicki. 1995. Distribution of calretinin, calbindin-D28k and parvalbumin in subcellular fractions of rat cerebellum: Effects of calcium. J. Neurochem. 65: 381-388.
63. 63. Winsky, L., K. R. Isaacs, and D. M. Jacobowitz. 1996. Calretinin mRNA and immunoreactivity in the medullary reticular formation of the rat: Colocalization with glutamate receptors. Brain Res. 741: 123-133.
64. 28K. Brain Res. 526: 303-307.
65. 65. Zigmond, M. J., T. G. Hastings, and E. D. Abercrombie. 1992. Neurochemical responses to 6-hydroxydopamine and L-DOPA therapy: Implications for Parkinson's disease. Ann. N.Y. Acad. Sci. 648: 71-86.